UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody ...

Merus N.V. (NASDAQ:MRUS) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN). Here’s what you need to know. What To Know: ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Merus (MRUS) keeps catching attention as its shares post impressive gains over the past month, rising around 46%. Recent investor interest appears closely linked to ongoing optimism around the company ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.

Incyte will make additional $80M investment in new partner and pay up to $350M milestones per program Incyte and Merus have signed a global strategic collaboration focused on the discovery and ...

Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific antibody. The slim slice of efficacy data, which Merus presented at the 2024 ...

A targeted cancer therapy from Merus has early clinical trial results suggesting it can treat tumors characterized by a genetic signature that hasn’t been addressed before, and the biotech is eying ...